INCB 62079Alternative Names: INCB62079
Latest Information Update: 13 Jan 2017
At a glance
- Originator Incyte Corporation
- Class Antineoplastics
- Mechanism of Action Fibroblast growth factor receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Liver cancer
Most Recent Events
- 12 Jan 2017 Preclinical trials in Liver cancer in USA before January 2017 (Incyte Corporation pipeline, January 2017)